摘要
目的探讨米氮平和西酞普兰对老年抑郁症的疗效和安全性。方法将72例老年抑郁症患者随机分为研究组和对照组,分别给予米氮平和西酞普兰治疗,疗程8周。采用汉密尔顿抑郁量表(HAMD)及副反应量表(TESS)评定疗效和不良反应。结果治疗8周后,研究组和对照组有效率分别为88.89%,86.11%(P>0.05)。两组治疗后HAMD总分、焦虑/躯体化因子分及睡眠障碍因子分均有明显下降(P<0.05或0.01),但研究组下降更迅速、更明显(P<0.05或0.01)。两组不良反应发生率和TESS评分均无明显差异(P>0.05)。结论与西酞普兰相比,米氮平治疗老年性抑郁症同样安全有效,但起效更快,对于改善失眠、焦虑、躯体化症状尤其有优势。
Objective To compare the efficacy and safety of mirtazapine and citalopram in the treatment of senile depression. Methods 72 senile patients with depression were randomly divided into the study group and the control group, and treated by mirtazapine and citalopram for 8 weeks respectively. The Hamilton Depression Rating Scale （HAMD） and the Treatment Emergent Sympton Scale （TESS） were used to evaluate the efficacy and adverse reactions. Methods After 8 weeks treatment, the effective rates in the study group and the control group were 88.89% and 86. 11% respectively, which showed no significant difference between the two groups （P〉0. 05）. The HAMD total score, anxiety/somatization factor score and the sleep disturbance factor score were decreased significantly in the two groups（ P 〈0. 05 or 0. 01）, but which in the study group was declined more rapidly and more obviously（ P 〈0.05 or 0.01）. The occurrence rate of the adverse reactions and the TESS scores had no significantly difference between the two groups （P 〉 0. 05）. Conclusion Compared with citalopram, mirtazapine is equally s^ffe and effective in the treatment of senile depression, but has the more quick onset of action and shows a significant advantage in the improvement of insomnia, anxiety and somatization symptoms.
出处
《中国药业》
CAS
2013年第15期89-91,共3页
China Pharmaceuticals
